Since 2018, regulators have linked contamination events to the recall of more than 40 finished drug products worldwide, forcing a fundamental shift in GMP inspection priorities. What initially emerged as a quality concern around nitrosamine in pharmaceuticals has since expanded into a broader regulatory focus on how related compounds can form, how risks are justified, and how control decisions remain traceable across the product lifecycle.
Today, inspectors no longer ask whether these impurities can occur. Instead, they assess where formation becomes plausible, how risks are evaluated, and why specific controls were selected within manufacturing and quality systems. When companies fail to connect chemistry, process design, and GMP decision-making, inspection findings increasingly point to systemic weaknesses rather than isolated contamination events.
Table of Contents
What are nitrosamine compounds?
In a GMP context, high-risk impurity formation falls within process-related and degradation-related categories that carry significant toxicological concern. Therefore, regulators treat this risk differently from routine impurities and expect structured classification supported by scientific rationale. Moreover, inspectors view formation risk as a quality system outcome, since gaps often reflect upstream decisions in materials, processes, and change management rather than isolated analytical failures.
Why nitrosamines matter in GMP inspections
Inspectors focus on impurity formation risks because they reveal how well a quality system anticipates issues, not just how it reacts to test results. Therefore, regulators start with process design, material controls, and change histories to assess whether formation could realistically occur. When governance weakens, these risks quickly expose systemic failures rather than isolated contamination events.
Typical GMP inspection findings linked to impurity formation risk
| Inspection focus area | What inspectors question | Common quality system weakness |
|---|---|---|
|
Process design |
Formation pathways not assessed |
Limited process understanding |
|
Raw materials |
Secondary amines or nitrites overlooked |
Weak supplier qualification |
|
Change management |
Changes made without reassessment |
Ineffective change control |
|
Solvent practices |
Recovered solvents not evaluated |
Gaps in impurity oversight |
|
Risk documentation |
Conclusions lack rationale |
Poor decision traceability |
This pattern explains why inspectors prioritize this topic during GMP reviews: it consistently exposes gaps in risk-based thinking, documentation, and lifecycle control.
How nitrosamines are formed in pharmaceutical manufacturing processes
In pharmaceutical manufacturing, impurity formation follows logical and traceable patterns shaped by process design, material selection, and quality decisions. Inspectors assess these patterns to determine whether manufacturers understand where risks may realistically emerge and whether controls align with that understanding.
To support this assessment, the infographic below visualizes how impurity formation can progress across key stages of pharmaceutical manufacturing.
After the infographic, this section explains how inspectors think when they assess formation risk, emphasizing process-driven decisions rather than standalone chemical reactions.
- Step 1 – Nitrosamine formation pathways in manufacturing environments
- Step 2 – Secondary amine nitrosation under process conditions
- Step 3 – Nitrite amine reaction conditions inspectors focus on
- Step 4 – Sources of nitrosamine compounds across materials and processes
Step 1 – Nitrosamine formation pathways in manufacturing environments
In pharmaceutical manufacturing, impurity formation often starts with process architecture, not with a single reaction step. Inspectors expect companies to identify where interactions between materials, conditions, and equipment could create unintended by-products. When manufacturers fail to map these pathways across the process, regulators usually question the depth of process understanding.
Step 2 – Secondary amine nitrosation under process conditions
Secondary amines can enter manufacturing streams through raw materials, solvents, or excipients. Under certain operating conditions, these substances may participate in reactions that generate unwanted by-products. During inspections, regulators focus on whether companies identified these inputs and assessed their behavior under real processing conditions.
Step 3 – Nitrite amine reaction conditions inspectors focus on
From an inspection standpoint, operating conditions drive risk. Parameters such as pH, temperature, and residence time often determine whether reactions become plausible. Inspectors review whether risk assessments consider worst-case conditions rather than ideal or assumed process states.
Step 4 – Sources of nitrosamine compounds across materials and processes
Beyond primary materials, unintended impurities may originate from recycled solvents, water systems, or packaging interactions. Inspectors expect manufacturers to evaluate these indirect sources as part of lifecycle oversight. When assessments focus too narrowly, regulators often identify gaps in contamination control strategy.
Data Integrity and Evidence Traceability in Nitrosamine Oversight
During GMP inspections, regulators link impurity formation to product contamination only when companies can trace decisions, data, and controls across the lifecycle. Inspectors do not accept test results alone; they expect clear evidence showing how risks were identified, evaluated, and controlled. Regulatory guidance, including FDA expectations for high-risk impurity control, reinforces this focus on data integrity and documented decision-making.
Nitrosamine impurities GMP requirements and inspection expectations
Under GMP, inspectors expect companies to manage high-risk impurity concerns through clear risk assessments, justified controls, and traceable decisions. They focus less on document volume and more on whether control strategies clearly link to identified risks. When this logic breaks, inspection findings usually point to quality system weaknesses, not technical errors.
What inspectors review when assessing impurity control
| GMP expectation | What inspectors look for | Common inspection gap |
|---|---|---|
|
Risk assessment |
Identification of formation drivers and worst-case scenarios |
Unsupported assumptions |
|
Control strategy |
Controls directly linked to risks |
Generic or copied controls |
|
Change management |
Updated risk review after changes |
Changes without reassessment |
|
Documentation |
Consistent rationale across records |
Disconnected documentation |
|
Lifecycle oversight |
Periodic review and re-evaluation |
One-time assessments |
The infographic below highlights the key areas inspectors consistently review when evaluating contamination risk during GMP inspections.
Final Words
In recent GMP inspections, regulators increasingly flag impurity risks during routine quality system reviews, even when no batch failure has occurred. Post-2019 inspection observations and Form 483 findings show that gaps in risk assessment logic, change control follow-up, and documentation consistency often trigger deeper regulatory scrutiny. Within this context, nitrosamine compounds continue to act as a reference point for how inspectors evaluate overall quality system maturity.
Therefore, companies that clearly connect risk identification, control strategy, and documented decisions reduce inspection friction. However, when this connection breaks, findings escalate quickly and expose systemic weaknesses. In today’s inspection environment, sustainable compliance depends on how well evidence, decisions, and controls align over time, not on isolated test results.
Nitrosamines Regulatory Compliance
We assist pharmaceutical teams in assessing and managing nitrosamines risks by aligning processes with ICH M7 requirements and current regulatory expectations.
FAQ
Impurity formation typically occurs when materials, process conditions, or changes interact in ways not fully assessed during development. In regulated manufacturing, inspectors expect companies to explain these pathways using process knowledge, not post-hoc test results.
Because compliance depends on risk anticipation, not outcomes alone. Inspectors review whether quality systems identified, evaluated, and controlled formation risks before testing not whether results happened to pass.
Regulators expect traceable evidence linking risk assessments, control strategies, change management, and analytical data. When records lack consistency or rationale, inspections often escalate to quality system findings rather than technical observations.
References
Alireza Zarei is the founder and CEO of Zamann Pharma Support GmbH in Germany. He pairs 20 years in GMP—beginning in a lab in 2005—with front-line global project delivery for companies such as Boehringer Ingelheim, Roche, BioNTech, Takeda, Fresenius Medical Care, Biotest, ratiopharm and others. He focuses on innovative validation and qualification procedures, master data management strategies, end-to-end LIMS implementation and care, with pragmatic advice on general Quality Management topics and management level OpEx consulting. Together with his team he also created Pharmuni.com as the leading GMP learning platform in the industry.